Malaysia signs an agreement with Merck & Co. to obtain 150,000 courses of the experimental drug Molnupiravir as part of a transition towards the endemic phase and "living with the COVID-19". (The Straits Times) COVID-19 pandemic in Malaysia, COVID-19 drug developmentCOVID-19 pandemic in AsiaCOVID-19 pandemic link embed save